pharma · Breast Cancer · Multiple Sclerosis (MS)
Hoffmann-La Roche
Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo
Phase 2 · small molecule · Obesity
RO7204239 is a small-molecule investigational agent being developed by Hoffmann-La Roche for obesity treatment. The program is currently in Phase 2 development and is being evaluated in combination with tirzepatide (Mounjaro, Eli Lilly), a GLP-1/GIP receptor agonist approved for weight management. The trial design is a
Internal code BC45538
RO7204239 is a small-molecule investigational agent being developed by Hoffmann-La Roche for obesity treatment. The program is currently in Phase 2 development and is being evaluated in combination with tirzepatide (Mounjaro, Eli Lilly), a GLP-1/GIP receptor agonist approved for weight management. The trial design is a randomized, double-blind, placebo-controlled study assessing efficacy, safety, and tolerability in participants with obesity or overweight status plus at least one weight-related comorbidity. Tirzepatide itself has achieved regulatory approval in the European Union (January 2026), Japan (December 2024), and the United States. Roche's combination strategy suggests exploration of synergistic mechanisms to enhance weight loss outcomes beyond monotherapy. The program remains in active development with no publicly disclosed peak sales projections or definitive timeline for regulatory milestones.
Obesity represents a significant unmet medical need globally, with limited pharmacological options despite high disease burden and associated comorbidities. Tirzepatide monotherapy has demonstrated substantial weight loss efficacy, but combination approaches may offer incremental benefits for patients with inadequate response or those seeking enhanced outcomes. Roche's entry into obesity pharmacotherapy via a combination strategy positions the company in a rapidly expanding market segment. The competitive landscape includes multiple approved agents across different mechanisms (GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others), but combination therapies remain relatively underdeveloped. The obesity indication represents substantial commercial opportunity given the large patient population, chronic treatment duration, and growing payer acceptance of weight-loss medications. Success in this Phase 2 trial could establish a differentiated positioning for RO7204239 and support advancement to pivotal Phase 3 studies, potentially enabling market entry within 3–5 years depending on regulatory pathway and trial outcomes.
Drug Class: Small-molecule investigational agent (RO7204239); combined with tirzepatide, a dual GLP-1/GIP receptor agonist.
Modality: Small molecule (RO7204239); tirzepatide is a peptide agonist.
Route of Administration: Subcutaneous injection (tirzepatide via KwikPen pre-filled pen in multiple dose strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg/dose).
Mechanism of Action: Not yet disclosed for RO7204239; tirzepatide acts as a dual GLP-1 and GIP receptor agonist.
Target: Not yet disclosed for RO7204239.
Related Therapies: Tirzepatide (Mounjaro) is the lead component; competitors in obesity/metabolic disease include liraglutide (Saxenda), semaglutide, and multiple oral agents (DPP-4 inhibitors, SGLT2 inhibitors).
First Approval: Tirzepatide approved in EU (29 January 2026), Japan (December 2024), and US (prior to 2024 based on NDA numbers).
Patent Status: Not yet disclosed.
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 combination trial ongoing
Randomized, double-blind, placebo-controlled Phase 2 trial assessing RO7204239 in combination with tirzepatide in participants with obesity or overweight with at least one weight-related comorbidity (NCT 2024-519561-22-00).
The obesity and metabolic disease market includes multiple approved therapies across distinct mechanisms. Tirzepatide (Mounjaro, Eli Lilly) itself is a direct competitor as the combination partner, having achieved approvals in the EU, Japan, and US. Other GLP-1 agonists such as liraglutide (Saxenda, Teva) are approved for weight management. The competitive set also includes DPP-4 inhibitors (Trajenta/linagliptin by Boehringer Ingelheim, Onglyza/saxagliptin by AstraZeneca, Vipidia/alogliptin by Takeda, Nesina/alogliptin by Lacuna Pharma), SGLT2 inhibitors (Forxiga/dapagliflozin by AstraZeneca, Invokana/canagliflozin by Teva), and other agents (Actos/pioglitazone by Alphapharm, Zynquista/canagliflozin by Lexicon, repaglinide formulations by Teva). Most competitors are approved for diabetes rather than obesity specifically. Roche's combination approach with RO7204239 and tirzepatide represents a differentiated strategy aimed at enhancing efficacy beyond monotherapy, though the specific mechanism and clinical benefit of RO7204239 remain undisclosed.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| TRAJENTA | Boehringer Ingelheim Pty Ltd | — | approved |
| ACTOS | Alphapharm Pty Ltd | — | approved |
| ONGLYZA | AstraZeneca | — | approved |
| VIPIDIA | Takeda | — | approved |
| REPAGLINIDE SUN | Teva Pharma GmbH | — | approved |
| NESINA | Lacuna Pharma Pty Ltd | — | approved |
| ZYNQUISTA | LEXICON PHARMACEUTICALS, INC. | — | approved |
| SAXENDA | Teva Pharma GmbH | — | approved |
| FORXIGA | AstraZeneca | — | approved |
| QTRILMET | Takeda | — | approved |
| TRAZEC | Teva Pharma GmbH | — | approved |
| INVOKANA | Teva Pharma GmbH | — | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: Tirzepatide (Mounjaro) approved 29 January 2026 by EMA; Marketing Authorization Holder: Eli Lilly Nederland B.V.; EMA Product Number EMEA/H/C/005620.
Japan: Tirzepatide approved December 2024 by PMDA.
United States: Tirzepatide approved; NDAs 215866 and 217806 (Eli Lilly and Co.). RO7204239 regulatory status not yet disclosed.
China (NMPA): Status not yet disclosed.
RO7204239 Regulatory Status: Investigational; Phase 2 development ongoing. No IND, CTA, or regulatory filing status disclosed for RO7204239 as a standalone agent or in combination.
RO7204239 is a small-molecule investigational drug being developed by Hoffmann-La Roche for obesity treatment, currently in Phase 2 clinical trials in combination with tirzepatide.
RO7204239 is being evaluated for obesity treatment in combination with tirzepatide in participants with obesity or overweight status plus at least one weight-related comorbidity.
Hoffmann-La Roche (Roche) is the sponsor and developer of RO7204239.
RO7204239 is in Phase 2 clinical development as of the latest available information.
Tirzepatide is a dual GLP-1/GIP receptor agonist approved for weight management and diabetes; it is manufactured by Eli Lilly and marketed as Mounjaro.
Yes, tirzepatide is approved in the European Union (29 January 2026), Japan (December 2024), and the United States.
RO7204239 is being studied in combination with tirzepatide, which is administered as a subcutaneous injection via pre-filled KwikPen in doses ranging from 2.5 to 15 mg; the administration route for RO7204239 alone is not yet disclosed.
The mechanism of action of RO7204239 has not yet been disclosed by Roche.
The molecular target of RO7204239 has not yet been disclosed.
Yes, a randomized, double-blind, placebo-controlled Phase 2 trial (NCT 2024-519561-22-00) is assessing RO7204239 in combination with tirzepatide in participants with obesity or overweight with at least one weight-related comorbidity.
The specific primary endpoints of the Phase 2 trial have not yet been disclosed.
The expected timeline for Phase 2 results has not yet been disclosed.
Competitors include liraglutide (Saxenda, Teva), semaglutide, and multiple oral agents such as DPP-4 inhibitors (Trajenta, Onglyza, Vipidia, Nesina), SGLT2 inhibitors (Forxiga, Invokana), and other metabolic agents.
The combination strategy suggests Roche believes RO7204239 may provide synergistic benefits with tirzepatide to enhance weight loss outcomes, though the specific rationale has not been disclosed.
RO7204239 is investigational and in Phase 2 development; no regulatory filings or approvals have been disclosed.
The internal code for the RO7204239 program is BC45538.
BC45538 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Roche's combination approach with RO7204239 and tirzepatide signals confidence in the obesity market and a strategy to differentiate via synergistic mechanisms. The use of tirzepatide—a proven, approved agent—as the backbone reduces development risk and accelerates time to potential clinical readout.
Competitive Implications: Success could establish a new combination standard in obesity treatment, potentially capturing patients with inadequate monotherapy response. However, the undisclosed mechanism of RO7204239 limits assessment of true differentiation versus existing therapies.
Development Catalysts: Phase 2 efficacy and safety data will be critical; positive results could support Phase 3 initiation. Regulatory feedback on combination strategy and potential accelerated pathways (e.g., breakthrough designation) would materially advance timelines.
Commercial Considerations: Obesity represents a large, growing market with increasing payer coverage. Combination therapies command premium pricing potential. However, tirzepatide's existing market presence and potential generic/biosimilar competition within 5–10 years may constrain long-term exclusivity.
Unmet Information: Mechanism of action, target, and specific clinical endpoints for RO7204239 remain proprietary; disclosure would clarify competitive positioning and clinical rationale.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.